{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:24:13Z","timestamp":1784233453474,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Calcitonin gene-related peptide (CGRP) plays an important role in cerebral vasodilation, so here we aim to quantify the impact of CGRP monoclonal antibody (mAb) therapy on cerebral hemodynamics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In 23 patients with chronic and episodic migraine, cerebral hemodynamic monitoring was performed (1) prior to and (2) 3-months into CGRP-mAb therapy. Transcranial Doppler monitored cerebral blood flow velocity (CBFv) in the middle cerebral artery (MCA) and posterior cerebral artery (PCA), from which cerebrovascular reactivity (CVR) and cerebral autoregulation (CA; <jats:italic>Mx-index<\/jats:italic>) were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CA was similar off and on treatment, in the MCA (<jats:italic>p<\/jats:italic>\u2009=\u20090.42) and PCA (<jats:italic>p<\/jats:italic>\u2009=\u20090.72). CVR was also unaffected by treatment, in the MCA (<jats:italic>p<\/jats:italic>\u2009=\u20090.38) and PCA (<jats:italic>p<\/jats:italic>\u2009=\u20090.92). CBFv and blood pressure were also unaffected. The subgroup of clinical responders (&amp;gt;50% reduction in migraine frequency) exhibited a small reduction in MCA-CBFv (6.0\u2009cm\/s; IQR: 1.1\u201312.4; <jats:italic>p<\/jats:italic>\u2009=\u20090.007) and PCA-CBFv (8.9\u2009cm\/s; IQR: 6.9\u201310.3; <jats:italic>p<\/jats:italic>\u2009=\u20090.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Dynamic measures of cerebrovascular physiology were preserved after 3\u2009months of CGRP-mAb therapy, but a small reduction in CBFv was observed in patients who responded to treatment. Subgroup findings should be interpreted cautiously, but further investigation may clarify if CBFv is dependent on the degree of CGRP inhibition or may serve as a biomarker of drug sensitivity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1399792","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:07:28Z","timestamp":1714468048000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of CGRP inhibitors on interictal cerebral hemodynamics in individuals with migraine"],"prefix":"10.3389","volume":"15","author":[{"given":"Sarah C.","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navpreet","family":"Reehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Favilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the trigeminal system in migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1440-1681.2004.03943.x","article-title":"Importance of calcitonin gene-related peptide, adenosine and reactive oxygen species in cerebral autoregulation under normal and diseased conditions","volume":"31","author":"Shin","year":"2004","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"578103","DOI":"10.3389\/fneur.2020.578103","article-title":"\u03b1CGRP-induced changes in cerebral and systemic circulation; a TCD study","volume":"11","author":"Visocnik","year":"2020","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10194-008-0036-8","article-title":"Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients","volume":"9","author":"Lassen","year":"2008","journal-title":"J Headache Pain"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"H11","DOI":"10.1152\/ajpheart.1994.266.1.H11","article-title":"Pharmacological evidence that calcitonin gene-related peptide is implicated in cerebral autoregulation","volume":"266","author":"Hong","year":"1994","journal-title":"Am J Phys"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25831","article-title":"Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice","volume":"88","author":"Mulder","year":"2020","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0333102419896760","article-title":"Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier","volume":"40","author":"Noseda","year":"2020","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0333102417736900","article-title":"Recognizing the role of CGRP and CGRP receptors in migraine and its treatment","volume":"39","author":"Edvinsson","year":"2019","journal-title":"Cephalalgia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.bjp.0707134","article-title":"Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery","volume":"150","author":"Edvinsson","year":"2007","journal-title":"Br J Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fphys.2018.01249","article-title":"The role of calcitonin gene related peptide (CGRP) in neurogenic vasodilation and its Cardioprotective effects","volume":"9","author":"Kee","year":"2018","journal-title":"Front Physiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.npep.2010.12.002","article-title":"Calcitonin gene-related peptide (CGRP) and its role in hypertension","volume":"45","author":"Smillie","year":"2011","journal-title":"Neuropeptides"},{"key":"ref15","first-page":"816","article-title":"Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man","volume":"77","author":"Portaluppi","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention","volume":"94","author":"Kudrow","year":"2020","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/0271678X211052588","article-title":"Reliability and validity of the mean flow index (mx) for assessing cerebral autoregulation in humans: a systematic review of the methodology","volume":"42","author":"Olsen","year":"2022","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e14923","DOI":"10.14814\/phy2.14923","article-title":"Reliability of the mean flow index (mx) for assessing cerebral autoregulation in healthy volunteers","volume":"9","author":"Olsen","year":"2021","journal-title":"Physiol Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejphar.2003.09.021","article-title":"In-depth characterization of CGRP receptors in human intracranial arteries","volume":"481","author":"Jansen-Olesen","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/00004647-200205000-00014","article-title":"Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature","volume":"22","author":"Oliver","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"173205","DOI":"10.1016\/j.ejphar.2020.173205","article-title":"The effects of CGRP in vascular tissue - classical vasodilation, shadowed effects and systemic dilemmas","volume":"881","author":"Sohn","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1124\/jpet.113.206458","article-title":"In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232","volume":"347","author":"Hostetler","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"895476","DOI":"10.3389\/fneur.2022.895476","article-title":"Cerebral blood flow and other predictors of responsiveness to Erenumab and Fremanezumab in migraine-a real-life study","volume":"13","author":"Nowaczewska","year":"2022","journal-title":"Front Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/0333102414552531","article-title":"Migraine and cerebral blood flow in the general population","volume":"35","author":"Loehrer","year":"2015","journal-title":"Cephalalgia"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0333102412474503","article-title":"Interictal cortical hyperresponsiveness in migraine is directly related to the presence of aura","volume":"33","author":"Datta","year":"2013","journal-title":"Cephalalgia"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2686689","article-title":"The responses to CGRP in the territory of the posterior cerebral artery in migraine","volume":"2022","author":"Visocnik","year":"2022","journal-title":"Biomed Res Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0333102420956692","article-title":"Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura","volume":"41","author":"Altamura","year":"2021","journal-title":"Cephalalgia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000015943","article-title":"Cerebrovascular reactivity evaluated by transcranial Doppler: reproducibility of different methods","volume":"9","author":"Totaro","year":"1999","journal-title":"Cerebrovasc Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1378\/chest.110.4.958","article-title":"Arterial blood gas changes during breath-holding from functional residual capacity","volume":"110","author":"Sasse","year":"1996","journal-title":"Chest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0333102418774299","article-title":"Cortical spreading depression as a site of origin for migraine: role of CGRP","volume":"39","author":"Close","year":"2019","journal-title":"Cephalalgia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e1897","DOI":"10.1212\/WNL.0000000000201008","article-title":"Blood pressure in patients with migraine treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study","volume":"99","author":"de Vries","year":"2022","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/head.14208","article-title":"Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data","volume":"61","author":"Dodick","year":"2021","journal-title":"Headache"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","article-title":"Hypertension: a new safety risk for patients treated with erenumab","volume":"61","author":"Saely","year":"2021","journal-title":"Headache"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medengphy.2021.01.003","article-title":"Reliability of the transcranial Doppler ultrasound-derived mean flow index for assessing dynamic cerebral autoregulation in healthy volunteers","volume":"89","author":"Riberholt","year":"2021","journal-title":"Med Eng Phys"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jns.2006.06.009","article-title":"Cerebrovascular reactivity over time course in healthy subjects","volume":"249","author":"Schwertfeger","year":"2006","journal-title":"J Neurol Sci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1399792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:07:32Z","timestamp":1714468052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1399792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":38,"alternative-id":["10.3389\/fneur.2024.1399792"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1399792","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"article-number":"1399792"}}